Table II.

Clinical and molecular characteristics of 144 patients with glioblastoma multiforme.

		Survivin expression
Variables	Total	High	Low	P-value
Sex
Female	51	23	28	0.384
Male	93	49	44
Age, years
>48	71	33	38	0.405
≤48	73	39	34
IDH mutation
Mutation	39	20	19	0.851
Wild type	105	52	53
TP53 mutation
Mutation	77	36	41	0.404
Wild type	67	36	31
EGFR mutation
Mutation	39	19	20	0.851
Wild type	105	53	52
ATRX mutation
Mutation	13	4	9	0.146
Wild type	131	68	63
TERT promoter mutation
Mutation	36	21	15	0.305
Wild type	65	31	34
MGMT methylation
Yes	61	34	27	0.368
No	71	34	37
KPS
>70	60	27	33	0.317
≤70	36	20	16
Resection
GTR	90	44	46	0.717
STR	46	24	22
Treatment
RT	22	11	11	0.946
RT+TZM	59	30	29
TCGA subtype
Proneural	33	20	13	0.165
Neural	12	0	12	<0.001
Classical	48	31	17	0.013
Mesenchymal	51	21	30	0.117

IDH, isocitrate dehydrogenase; TP53, tumor suppressor p53; EGFR, epidermal growth factor receptor; TERT, telomerase reverse transcriptase; MGMT, O⁶-alkylguanine DNA alkyltransferase; KPS, Karnofsky performance status; GTR, gross total resection; STR, subtotal resection; RT, radiotherapy; TMZ, temozolomide; TCGA, The Cancer Genome Atlas.